Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.60-0.26 (-3.31%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close7.86
Bid7.46 x 500
Ask8.00 x 1000
Day's Range7.59 - 7.89
52wk Range4.25 - 10.71
1y Target EstN/A
Market Cap437.54M
P/E Ratio (ttm)-3.45
Avg Vol (3m)216,926
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application

    Sorrento), has filed the Effectiveness and Target Animal Safety major technical sections of the New Animal Drug Application (NADA) for the control of pain associated with bone cancer in dogs.  ARK was granted a Minor Use/ Minor Species (MUMS) Drug Designation for ARK-001, a proprietary formulation containing the active ingredient Resiniferatoxin (also known as RTX) in June 2015.  Under the MUMS designation, ARK seeks the conditional approval of RTX and plans to complete the balance of the NADA application in 2017. RTX is a potent agonist of the TRPV1 receptor that is expressed on afferent nerves.  A single injection of RTX can irreversibly ablate these nerves and represents a method of chemical surgery with extreme selectivity since the effect of a single treatment should endure for the lifetime of the animal.  Afferent nerves are hyper-activated in many neurogenic inflammatory states which result in chronic pain and tissue damage in a variety of conditions including cancer pain, osteoarthritis, navicular syndrome and idiopathic cystitis.

  • PR Newswire17 days ago

    Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell

    SAN DIEGO, Sept. 13, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Miranda Toledano has been appointed Executive Vice President of Corporate Development of Sorrento and President of LA Cell, Sorrento's Joint Venture with City of Hope. Ms. Toledano joins Sorrento with 18 years of principal investment, financing and strategic advisory experience in the biopharmaceutical sector.  Since 2012, Miranda served as Head of Healthcare Investment Banking at MLV & Co., now an FBR company, where she completed over 110 IPO and follow on equity offerings totaling over $4 billion in aggregate value.  Prior to joining MLV, Miranda served in the investment group of Royalty Pharma where she focused on acquiring best in class biologic therapeutics targeting oncology, auto-immune and neurodegenerative indications.

  • PR Newswirelast month

    Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City

    "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at two upcoming conferences in New York City. Sorrento will also be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.  Sorrento will present on September 13th at 12:30 pm (ET). Sorrento will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.